Tirzepatide for weight-linked endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have endometrial cancer and be scheduled for a hysterectomy.
- Your body mass index (BMI) must be 30 or higher.
- Your cancer must be early-stage and confined to the uterus.
- You must be 18 or older.
- You must agree to attend all study visits and have internet access.
- You cannot be taking certain medications that affect metabolism, including insulin for diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if tirzepatide, a drug that helps with weight loss, can improve outcomes for women with obesity and certain early-stage endometrial conditions before a planned hysterectomy.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
This study tests whether a diabetes medication called tirzepatide, combined with a hormone-releasing device, can help shrink or stop early-stage endometrial cancer (cancer of the uterine lining) in patients who are overweight and either cannot have surgery right away or prefer to delay it. The goal is to see if this approach can be an alternative to immediate surgery.
This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.
This trial tests the safety and effectiveness of tirzepatide, a once-weekly injection, for weight loss in people with obesity. It might be an option if you have a BMI of 27 or higher with weight-related health problems, or a BMI of 35 or higher, and live in or near Asunción, Paraguay.
This study tests whether a weight-loss medication (tirzepatide) can help shrink early-stage, low-grade endometrial cancer or atypical hyperplasia while you keep your uterus for future pregnancy. It is designed for women who are overweight and wish to preserve their fertility.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.